Therapeutic Asset Ratings

705 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Thiotepa Severe Osteopetrosis	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Thiotepa Sly Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Thiotepa Sphingolipidoses	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Thiotepa Sphingomyelin Deficiency	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Thiotepa Zellweger Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Iopamidol Tumor Of Duodenum	Masonic Cancer Center, University of Minnesota	P2	CCC (52)
Iopamidol Pancreatic Neoplasm	Masonic Cancer Center, University of Minnesota	P2	CCC (52)
Cyclophosphamide Relapsed Adult AML	Masonic Cancer Center, University of Minnesota	P1/2	CCC (52)
Fludarabine Relapsed Adult AML	Masonic Cancer Center, University of Minnesota	P1/2	CCC (52)
Allopurinol Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Allopurinol Follicular Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Allopurinol Marginal Zone Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Allopurinol Myelofibrosis	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Acute Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Hematopoietic And Lymphoid Cell Neoplasm	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Lymphoblastic Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Minimal Residual Disease	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Brexucabtagene Autoleucel Large B-Cell Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Breyanzi Injectable Product Large B-Cell Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
HUMAN CULTURE EXPANDED GENETICALLY MODIFIED AUTOLOGOUS T CELLS FOR CELL-BASED GENE THERAPY. CELLS ARE DERIVED FROM ISOLATED BLOOD OF THE PATIENT AND ARE TRANSDUCED WITH NON-REPLICATIVE SELF-INACTIVATING (SIN) HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) BASED LENTIVIRAL VECTOR (LVV) PSEUDOTYPED WITH THE VESICULAR STOMATITIS VIRUS GLYCOPROTEIN G (VSV-G) ENVELOPE PROTEIN, AND ENCODING THE C11D5.3 ANTI-TNF RECEPTOR SUPERFAMILY MEMBER 17 (TNFRSF17, BCMA) SINGLE CHAIN VARIABLE FRAGMENT (SCFV) CD8/4-1BB/CD3ZETA CHIMERIC ANTIGEN RECEPTOR (CAR) UNDER THE TRANSCRIPTIONAL CONTROL OF THE MYELOPROLIFERATIVE SARCOMA VIRUS ENHANCER, NEGATIVE CONTROL REGION DELETED, DL587REV PRIMER-BINDING SITE SUBSTITUTED (MND) PROMOTE Large B-Cell Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Keppra Hematologic Malignancy	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Keppra Lymphoblastic Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Keppra Minimal Residual Disease	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Tisagenlecleucel Large B-cell Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Acute Lymphoblastic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (48)

Showing 551 to 575 of 705 assets

PreviousPage 23 of 29Next